U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C16H12O3
Molecular Weight 252.2647
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ANISINDIONE

SMILES

COC1=CC=C(C=C1)C2C(=O)C3=C(C=CC=C3)C2=O

InChI

InChIKey=XRCFXMGQEVUZFC-UHFFFAOYSA-N
InChI=1S/C16H12O3/c1-19-11-8-6-10(7-9-11)14-15(17)12-4-2-3-5-13(12)16(14)18/h2-9,14H,1H3

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including: http://www.druglib.com/activeingredient/anisindione/ | http://en.pharmacodia.com/web/drug/1_7940.html

Anisindione (brand name Miradon) is a synthetic anticoagulant and an indanedione derivative with action similar to these of Warfarin. It is indicated for the prophylaxis and treatment of venous thrombosis and its extension, the treatment of atrial fibrillation with embolization, the prophylaxis and treatment of pulmonary embolism, and as an adjunct in the treatment of coronary occlusion. Anisindione prevents the formation of active procoagulation factors II, VII, IX, and X, as well as the anticoagulant proteins C and S, in the liver by inhibiting the vitamin K–mediated gamma-carboxylation of precursor proteins. Hemorrhage and/or necrosis are among the hazards of treatment with any anticoagulant and are the main serious complications of therapy. Drugs that have been reported to diminish oral anticoagulant response, ie, decreased prothrombin time response, in man significantly include: adrenocortical steroids; alcohol; antacids; antihistamines; barbiturates and others.

Originator

Sources: DOI: 10.1021/ja01299a005

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
MIRADON

Approved Use

For the prophylaxis and treatment of venous thrombosis and its extension, the treatment of atrial fibrillation with embolization, the prophylaxis and treatment of pulmonary embolism, and as an adjunct in the treatment of coronary occlusion.

Launch Date

-4.02105598E11
Primary
MIRADON

Approved Use

For the prophylaxis and treatment of venous thrombosis and its extension, the treatment of atrial fibrillation with embolization, the prophylaxis and treatment of pulmonary embolism, and as an adjunct in the treatment of coronary occlusion.

Launch Date

-4.02105598E11
Preventing
MIRADON

Approved Use

For the prophylaxis and treatment of venous thrombosis and its extension, the treatment of atrial fibrillation with embolization, the prophylaxis and treatment of pulmonary embolism, and as an adjunct in the treatment of coronary occlusion.

Launch Date

-4.02105598E11
Primary
MIRADON

Approved Use

For the prophylaxis and treatment of venous thrombosis and its extension, the treatment of atrial fibrillation with embolization, the prophylaxis and treatment of pulmonary embolism, and as an adjunct in the treatment of coronary occlusion.

Launch Date

-4.02105598E11
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
4 day
unknown, oral
ANISINDIONE plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
600 mg multiple, oral (starting)
Studied dose
Dose: 600 mg
Route: oral
Route: multiple
Dose: 600 mg
Sources: Page: p.76
unhealthy, 47 - 89
n = 52
Health Status: unhealthy
Condition: Vascular disease
Age Group: 47 - 89
Sex: M+F
Population Size: 52
Sources: Page: p.76
PubMed

PubMed

TitleDatePubMed
Anticoagulation with anisindione in patients who are intolerant of warfarin.
1994 Jun
Prediction of pharmacological and xenobiotic responses to drugs based on time course gene expression profiles.
2009 Dec 2
Patents

Patents

Sample Use Guides

Initial dosage of anisindione is 300 mg the first day, 200 mg the second day, and 100 mg the third day. Maintenance dosage will vary between 25 to 250 mg a day.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Name Type Language
ANISINDIONE
HSDB   INN   MART.   MI   ORANGE BOOK   VANDF   WHO-DD  
INN  
Official Name English
2-(P-METHOXYPHENYL)INDANE-1,3-DIONE
Common Name English
Anisindione [WHO-DD]
Common Name English
ANISINDIONE [HSDB]
Common Name English
ANISINDIONE [MART.]
Common Name English
NSC-759629
Code English
MIRADON
Brand Name English
ANISINDIONE [MI]
Common Name English
ANISINDIONE [ORANGE BOOK]
Common Name English
ANISINDIONE [VANDF]
Common Name English
anisindione [INN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C263
Created by admin on Fri Dec 15 15:14:53 UTC 2023 , Edited by admin on Fri Dec 15 15:14:53 UTC 2023
Code System Code Type Description
WIKIPEDIA
ANISINDIONE
Created by admin on Fri Dec 15 15:14:53 UTC 2023 , Edited by admin on Fri Dec 15 15:14:53 UTC 2023
PRIMARY
INN
854
Created by admin on Fri Dec 15 15:14:53 UTC 2023 , Edited by admin on Fri Dec 15 15:14:53 UTC 2023
PRIMARY
NCI_THESAURUS
C47398
Created by admin on Fri Dec 15 15:14:53 UTC 2023 , Edited by admin on Fri Dec 15 15:14:53 UTC 2023
PRIMARY
DRUG CENTRAL
222
Created by admin on Fri Dec 15 15:14:53 UTC 2023 , Edited by admin on Fri Dec 15 15:14:53 UTC 2023
PRIMARY
MERCK INDEX
m1931
Created by admin on Fri Dec 15 15:14:53 UTC 2023 , Edited by admin on Fri Dec 15 15:14:53 UTC 2023
PRIMARY Merck Index
HSDB
3205
Created by admin on Fri Dec 15 15:14:53 UTC 2023 , Edited by admin on Fri Dec 15 15:14:53 UTC 2023
PRIMARY
RXCUI
17941
Created by admin on Fri Dec 15 15:14:53 UTC 2023 , Edited by admin on Fri Dec 15 15:14:53 UTC 2023
PRIMARY RxNorm
EVMPD
SUB05520MIG
Created by admin on Fri Dec 15 15:14:53 UTC 2023 , Edited by admin on Fri Dec 15 15:14:53 UTC 2023
PRIMARY
EPA CompTox
DTXSID3022611
Created by admin on Fri Dec 15 15:14:53 UTC 2023 , Edited by admin on Fri Dec 15 15:14:53 UTC 2023
PRIMARY
IUPHAR
6960
Created by admin on Fri Dec 15 15:14:53 UTC 2023 , Edited by admin on Fri Dec 15 15:14:53 UTC 2023
PRIMARY
ECHA (EC/EINECS)
204-186-6
Created by admin on Fri Dec 15 15:14:53 UTC 2023 , Edited by admin on Fri Dec 15 15:14:53 UTC 2023
PRIMARY
CHEBI
133809
Created by admin on Fri Dec 15 15:14:53 UTC 2023 , Edited by admin on Fri Dec 15 15:14:53 UTC 2023
PRIMARY
DRUG BANK
DB01125
Created by admin on Fri Dec 15 15:14:53 UTC 2023 , Edited by admin on Fri Dec 15 15:14:53 UTC 2023
PRIMARY
PUBCHEM
2197
Created by admin on Fri Dec 15 15:14:53 UTC 2023 , Edited by admin on Fri Dec 15 15:14:53 UTC 2023
PRIMARY
FDA UNII
S747T1ERAJ
Created by admin on Fri Dec 15 15:14:53 UTC 2023 , Edited by admin on Fri Dec 15 15:14:53 UTC 2023
PRIMARY
ChEMBL
CHEMBL712
Created by admin on Fri Dec 15 15:14:53 UTC 2023 , Edited by admin on Fri Dec 15 15:14:53 UTC 2023
PRIMARY
CAS
117-37-3
Created by admin on Fri Dec 15 15:14:53 UTC 2023 , Edited by admin on Fri Dec 15 15:14:53 UTC 2023
PRIMARY
SMS_ID
100000086948
Created by admin on Fri Dec 15 15:14:53 UTC 2023 , Edited by admin on Fri Dec 15 15:14:53 UTC 2023
PRIMARY
NSC
759629
Created by admin on Fri Dec 15 15:14:53 UTC 2023 , Edited by admin on Fri Dec 15 15:14:53 UTC 2023
PRIMARY